Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Summit Therapeutics buys Discuva for cash and stock

Executive Summary

Expanding its infectious disease pipeline, Summit Therapeutics PLC acquired private fellow UK-based firm Discuva Ltd. for £5mm ($6.68mm) in cash and £5mm in stock (2.93mm new ordinary shares at £1.70 each, a 2.7% premium).
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
      • Molecular Diversity
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Stock
    • Intra-Biotech Deal
    • Full Acquisition
    • Payment Includes Cash
    • Acquisition of Private Biotech

Related Companies